Tag Archive for: Venture Capital

Novo Holdings Joins €30M Series A Financing for Asgard Therapeutics, Leader In In Vivo Cell Reprogramming To Treat Cancer

/in

Financing to advance first platform designed to reprogram cancer cells into immune cells as pan-tumoral cancer treatment Novo Holdings participation follows earlier investment and incubation through seed phase Financing co-led by RV Invest and Johnson & Johnson Innovation, joined by existing investors Boehringer Ingelheim Venture Fund and Industrifonden COPENHAGEN – March 14th, 2024 – Novo Holdings, […]

Read more

Novo Holdings Venture Investments 2023 Newsletter: A record year advancing innovative therapies for patients

/in

18 new portfolio investments Five portfolio companies acquired $766 million invested and committed $600 million of cash exit proceeds San Francisco, Boston, London, and Copenhagen, Denmark, 5 March 2024 – The Novo Holdings Venture Investments team today published its review of 2023 – a record year advancing innovative therapies for patients. Read more…

Read more

Curve Therapeutics raises £40.5 million to turbocharge discovery platform and advance breakthrough pipeline

/in

Series A financing led by Pfizer Ventures with new investors Columbus Venture Partners and British Patient Capital which join founding investor Advent Life Sciences and seed investor Epidarex Capital Goal to advance proprietary discovery platform and progress pipeline of assets addressing challenging cancer targets into the clinic Southampton, UK, 27 February 2023 – Curve Therapeutics […]

Read more

Can private markets continue to drive development in Life Sciences? – Insights from Optimum’s Healthcare Conference

/in ,

We were proud to host a fantastic panel chaired by BioCentury’s European Editor Stephen Hansen with Soren Moller, Managing Partner of Novo Seeds; Karin Kleinhans, Partner of MRL Ventures Fund; Hakan Goker, Managing Director of M Ventures; Roel Bulthuis, Managing Partner at Inkef. This panel of Venture Capital (VC) investors discussed the strength of private […]

Read more

Merck KGaA, Darmstadt, Germany, Expands Corporate Venture Fund M Ventures with a New Investment of € 600 Million

/in

Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the expansion of its strategic, corporate venture capital arm M Ventures Darmstadt, Germany, December 8, 2021: Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the expansion of its strategic, corporate venture capital arm M Ventures. The new investment of € […]

Read more